These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35366939)

  • 1. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
    Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
    J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15
    Chen SMY; Li B; Nicklawsky AG; Krinsky AL; Brunetti T; Woolaver RA; Wang X; Chen Z; Young CD; Gao D; Wang XJ; Wang JH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32916850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.
    Shivarudrappa AH; John J; Vashisht M; Ge H; Liu S; Chen J; Siddoway K; Dong R; Chen Z; Wang JH
    Front Immunol; 2024; 15():1405318. PubMed ID: 39055715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors.
    Chen Z; John J; Wang JH
    Front Oncol; 2022; 12():995434. PubMed ID: 36330485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
    John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
    Front Immunol; 2022; 13():992630. PubMed ID: 36330507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
    Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
    Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders.
    John J; Chen SMY; Woolaver RA; Ge H; Vashisht M; Huang Z; Chen Z; Wang JH
    Front Immunol; 2023; 14():1100520. PubMed ID: 37051229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
    Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.
    Muijlwijk T; Nijenhuis DNLM; Ganzevles SH; Brink A; Ke C; Fass JN; Rajamanickam V; Leemans CR; Koguchi Y; Fox BA; Poell JB; Brakenhoff RH; van de Ven R
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma.
    Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C
    Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
    Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
    Front Immunol; 2022; 13():794251. PubMed ID: 35355980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
    O'Connell BC; Hubbard C; Zizlsperger N; Fitzgerald D; Kutok JL; Varner J; Ilaria R; Cobleigh MA; Juric D; Tkaczuk KHR; Elias A; Lee A; Dakhil S; Hamilton E; Soliman H; Peluso S
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39214650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.